𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The early use of disease-modifying antirheumatic drugs in rheumatoid arthritis

✍ Scribed by Edward S. Mongan

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
134 KB
Volume
33
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

American College of Rheumatology 2008 re
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
✍ Saag, Kenneth G. ;Teng, Gim Gee ;Patkar, Nivedita M. ;Anuntiyo, Jeremy ;Finney, πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 315 KB πŸ‘ 2 views

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be v

Delay to institution of therapy and indu
Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
✍ Timo MΓΆttΓΆnen; Pekka Hannonen; Markku Korpela; Martti NissilΓ€; Hannu Kautiainen; πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 59 KB πŸ‘ 2 views

## Abstract ## Objective To study the impacts of 1) the delay from the onset of symptoms to the institution of disease‐modifying antirheumatic drug (DMARD) therapy, 2) two treatment strategies (treatment with a combination of DMARDs or with a single drug), and 3) the presence of HLA–DRB1 alleles (

Medical resource use and costs among rhe
Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy
✍ Griffiths, Robert I. ;Bar-Din, Miriam ;MacLean, Catherine H. ;Sullivan, Erin M. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 201 KB πŸ‘ 1 views

## Objective: To identify costs among rheumatoid arthritis (ra) patients receiving alternative disease-modifying antirheumatic drug (dmard) therapies. ## Methods: Using managed care organization data, we identified members who (a) were prescribed any dmard therapy for two consecutive months betwe